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AbsTrACT
background Frontotemporal dementia (FTD) is a 
heterogeneous neurodegenerative disorder presenting 
clinically with personality change (behavioural variant 
FTD (bvFTD)) or language deficits (primary progressive 
aphasia (ppa)). about a third of FTD is familial with 
mutations in GRN, MAPT and C9orf72 being the major 
genetic causes. Robust biomarkers of the underlying 
pathology are still lacking in FTD with no markers 
currently being able to distinguish those with tau and 
TDp-43 inclusions during life.
Methods This study used an ultrasensitive single 
molecule methodology to measure plasma tau 
concentrations in 176 participants: 71 with bvFTD, 83 
with ppa and 22 healthy controls. The patient group 
included 36 with pathogenic mutations in either 
MAPT (n=12), GRN (n=9) or C9orf72 (n=15). Group 
comparisons were performed between clinical and 
genetic groups and controls using a linear regression 
model with bias-corrected bootstrap cIs. correlative 
analyses were performed to investigate associations with 
measures of disease severity and progression.
results higher plasma tau concentrations were seen 
in bvFTD (mean 1.96 (sD 1.07) pg/mL) and ppa (2.65 
(2.15) pg/mL) compared with controls (1.67 (0.50) 
pg/mL). Investigating the ppa group further showed 
significantly higher levels compared with controls in 
each of the ppa subtypes (non-fluent, semantic and 
logopenic variants, as well as a fourth group not meeting 
criteria for one of the three main variants). In the genetic 
groups, only the MAPT group had significantly increased 
concentrations (2.62 (1.39) pg/mL) compared with 
controls. No significant correlations were seen with 
cross-sectional or longitudinal brain volumes, serum 
neurofilament light chain concentrations or disease 
duration.
Conclusion plasma tau levels are increased in FTD in 
all clinical groups, but in the genetic subtypes only in 
MAPT mutations, the group of patients who definitively 
have tau pathology at postmortem. Future studies 
will be required in pathologically confirmed cohorts to 
investigate this association further, and whether plasma 
tau will be helpful in differentiating patients with FTD 
with tau from those with other pathologies.
INTroduCTIoN
Frontotemporal dementia (FTD) is a common 
cause of early onset dementia presenting clini-
cally with behavioural change (behavioural variant 
FTD (bvFTD)) or language impairment (primary 
progressive aphasia (PPA)) and pathologically, with 
inclusions containing usually either tau or TAR 
DNA-binding protein 43 (TDP-43). However, clin-
icopathological correlation is poor and diagnosing 
the correct proteinopathy during life is difficult 
except when a genetic cause is present (mutations 
in MAPT cause tau pathology, while mutations in 
GRN and C9orf72 cause TDP-43 pathology) or 
for certain phenotypes (eg, the semantic variant of 
PPA and FTD with motor neuron disease (MND) 
are both commonly associated with TDP-43 
pathology).1
Current biomarkers (including cerebrospinal 
fluid (CSF) measures of tau and TDP-43) do not 
accurately identify the underlying proteinopathy 
in vivo in FTD, and therefore novel measures are 
being investigated,1 including assays utilising blood 
samples which are less invasive than CSF. Recently, 
an ultrasensitive methodology of measuring plasma 
tau has been developed which has shown raised 
concentrations in Alzheimer’s disease,2 but has yet 
to be examined in FTD.
In this study, we aimed to investigate whether the 
levels of plasma tau are increased in patients with 
FTD compared with healthy controls, and in partic-
ular whether they vary between FTD subgroups.
MeThods
study participants
Plasma was available from 176 consecutively 
recruited participants from the University College 
London FTD cohort studies: 71 participants with 
bvFTD3 (of which three had concurrent MND 
(FTD-MND)4), 83 with PPA5 (23 with the semantic 
variant of PPA (svPPA), 33 with the non-fluent 
variant of PPA (nfvPPA), 18 with the logopenic 
variant of PPA (lvPPA) and nine who did not fit 
diagnostic criteria for any of these subtypes, named 
PPA-not otherwise specified (PPA-NOS)6) and 22 
healthy control participants (table 1).
Of the 155 participants with bvFTD or PPA, 37 
(14 with bvFTD, seven with svPPA, 10 with nfvPPA 
and six with lvPPA) had also had CSF collected 
and analysed for β-amyloid (Aβ1–42), total tau 
(t-tau) and phosphorylated tau (p-tau181) using 
the INNOTEST assays (Fujirebio Europe, Gent, 
Belgium).
Age at sample collection and gender were 
significantly different in controls compared with 
bvFTD (younger and more men in bvFTD group) 
with no significant difference between controls 
and PPA (table 1). All further statistical analyses 
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Table 1 Demographics and plasma tau concentrations in patients 
and controls
N
Age, mean 
(sd)
Gender, 
%male
disease 
duration, mean 
(sd)
Tau (pg/mL), 
mean (sd)
bvFTD 71 64.2 (8.1) 79 6.2 (4.4) 1.96 (1.07)
PPA 83 67.1 (8.2) 59 4.9 (2.6) 2.65 (2.15)
svPPA 23 65.4 (7.2) 52 5.5 (2.6) 2.47 (1.57)
nfvPPA 33 69.7 (9.3) 52 4.5 (2.7) 2.88 (2.88)
lvPPA 18 66.1 (7.6) 72 4.9 (2.5) 2.21 (1.22)
PPA-NOS 9 64.1 (4.7) 78 4.6 (2.0) 3.15 (1.76)
Controls 22 68.7 (6.5) 41 N/A 1.67 (0.50)
PPA subgroups are shown in italics.
bvFTD, behavioural variant FTD; FTD, frontotemporal dementia; lvPPA, logopenic 
variant of PPA; non-fluent variant of PPA; PPA, primary progressive aphasia; PPA-
NOS, PPA-not otherwise specified; svPPA, semantic variant of PPA.
were therefore adjusted for age and gender. Disease duration 
at sample collection was not significantly different between 
groups (table 1). Thirty-six participants had a pathogenic muta-
tion in the MAPT (12), GRN (9) or C9orf72 (15) genes, and a 
subanalysis was performed comparing these genetic groups with 
controls. Mean (SD) age at sample collection was 58.6 (6.2) 
years for the MAPT group, 63.1 (3.3) for GRN and 65.1 (6.2) for 
C9orf72—both MAPT and GRN were significantly younger than 
controls. Ninety-two per cent of patients with MAPT mutations 
were male (significantly more than controls), while 56% of GRN 
and 73% of C9orf72 cases were male (no significant difference 
from controls). No significant differences were seen in disease 
duration between the genetic subgroups: MAPT 6.8 (4.6) years, 
GRN 4.1 (3.3), and C9orf72 7.8 (4.3).
Plasma tau measurements
EDTA plasma samples were collected from the participants, 
processed and stored at −80°C following standardised proce-
dures. Plasma level concentrations were measured using the 
Human Total Tau kit (Quanterix, Boston, Massachusetts, USA) 
with the Simoa HD-1 Analyser (Quanterix, Boston, Massachu-
setts, USA). Briefly, samples, magnetic beads coated with Tau5 
monoclonal capture antibody, and HT7 and BT2 monoclonal 
biotinylated detector antibodies were combined. Antibody 
epitopes in the mid-region of tau make the assay sensitive to 
normal and phosphorylated tau, including most of the known 
protein isoforms. Thereafter, the capture beads were resus-
pended with streptavidin-β-galactosidase (SBG) and resorufin 
β-D-galactopyranoside (RPG) and transferred to the Simoa 
disk. Each bead fits into a microwell in the disk and if tau has 
been captured the β-galactosidase hydrolyses the RGP substrate 
which generates a fluorescent signal whose concentration can be 
measured against a standard curve derived from known concen-
trations of recombinant tau. The lower limit of detection for the 
assay is 0.019 pg/mL and the intra-assay coefficient of variation 
was 4.7% (all samples were analysed in duplicate on one occa-
sion using one batch of reagents).
Correlative analyses
In order to assess the association of plasma tau with disease in 
FTD, a number of measures were also assessed. As measures of 
disease severity, disease duration was measured as the differ-
ence between the number of years between when the sample 
was taken and symptom onset, and cross-sectional brain 
volumes were assessed in those with available neuroimaging: of 
the patients with FTD, 111 (57 bvFTD, 20 svPPA, 29 nfvPPA 
and five PPA-NOS) had volumetric T1 MRI performed usually 
on the day of blood sampling (mean (SD) 0.0 (0.2) years from 
sample to scan), with cortical (frontal, temporal, parietal, occip-
ital, insula and cingulate) and subcortical (hippocampus and 
amygdala) regions parcellated using an atlas propagation and 
label fusion strategy as previously described.7 As measures of 
disease progression, serum neurofilament light chain concen-
trations were available in 55 of the FTD patient cohort,8 and 
brain atrophy rate was measured in 32 patients (19 bvFTD, 
three svPPA, seven nfvPPA and three PPA-NOS) who had had 
follow-up brain imaging at a mean (SD) of 1.1 (0.2) years after 
the baseline scan.
Correlative analyses of plasma tau with CSF t-tau and p-tau181 
were also performed.
statistical analysis
Plasma tau data were not normally distributed (D’Agosti-
no-Pearson omnibus normality test); hence, groups were 
compared by examining contrasts between the group means 
using a linear regression model in STATA V.14 with 95% 
bias-corrected bootstrap CIs with 1000 replicates, adjusting for 
age and gender. The Spearman’s correlation coefficient was used 
to investigate the association between plasma tau in patients and 
each of the measures of disease severity and progression.
resuLTs
The mean plasma tau concentration was significantly higher in 
both bvFTD (mean 1.96 (SD 1.07) pg/mL) and PPA (2.65 (2.15) 
pg/mL) compared with controls (1.67 (0.50) pg/mL) (figure 1a): 
adjusted difference in means for bvFTD versus controls (0.46; 
95% CI 0.03 to 0.96), PPA versus controls (1.08; 95% CI 0.59 
to 1.65). Concentrations were also significantly higher in PPA 
compared with bvFTD (0.62; 95% CI 0.15 to 1.30).
In a clinical subgroup analysis, concentrations in the PPA 
subgroups were 2.47 (1.57) pg/mL in svPPA, 2.88 (2.88) pg/mL 
in nfvPPA, 2.21 (1.22) pg/mL in lvPPA and 3.15 (1.76) pg/mL 
in PPA-NOS (figure 1b). All subgroups were significantly higher 
than controls: svPPA (0.80; 95% CI 0.38 to 1.55); nfvPPA (1.34; 
95% CI 0.47 to 2.58); PPA-NOS (1.65; 95% CI 0.54 to 2.88); 
lvPPA (0.74; 95% CI 0.06 to 1.50). However, no significant 
differences were seen between disease groups.
In the genetic subgroup analysis, plasma tau concentrations 
were 2.62 (1.39) pg/mL in the MAPT group, 2.22 (1.60) pg/
mL in the C9orf72 group and 1.93 (0.70) pg/mL in the GRN 
group (figure 1c). Only the MAPT group had significantly higher 
concentrations than controls (adjusted difference in means 1.16 
(95% CI 0.25 to 2.19); GRN vs controls 0.33 (95% CI −0.21 to 
0.98); C9orf72 vs controls 0.73 (95% CI −0.10 to 1.77)) with 
no significant difference between the disease groups.
ROC curve analyses showed a relatively poor ability to distin-
guish disease groups from controls for the majority of the clin-
ical and genetic groups apart from PPA-NOS and MAPT which 
both had an area under the curve (AUC) of >0.75: AUC for 
bvFTD was 0.53, all PPA 0.65; svPPA 0.67, nfvPPA 0.60, lvPPA 
0.65, PPA-NOS 0.77; MAPT 0.77, GRN 0.59 and C9orf72 0.51.
In the subgroup of 37 patients with CSF, nine had a t-tau/
Aβ1-42 ratio of >1 (considered likely to be consistent with 
underlying Alzheimer’s disease pathology9: 0 bvFTD, one svPPA, 
two nfvPPA and six lvPPA) and the other 28 had a ratio of <1 
(14 bvFTD, six svPPA, eight nfvPPA and 0 lvPPA). The mean 
(SD) plasma tau concentration was 2.31 (1.50) for the >1 group 
and 2.41 (2.45) for the <1 group. Both groups had tau levels 
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Figure 1 plasma tau concentrations in participants comparing: (a) behavioural variant frontotemporal dementia (bvFTD), primary progressive aphasia 
(ppa) and healthy controls; (B) ppa subtypes: non-fluent variant (nfvppa), semantic variant (svppa), logopenic variant (lvppa) and a group not fitting criteria 
for any of the three main variants, ppa-not otherwise specified (ppa-NOs) and (c) genetic subtypes: microtubule-associated protein tau (MAPT), C9orf72 
and progranulin (GRN).
significantly greater than controls (adjusted difference in means 
ratio >1 vs controls 0.84 (95% CI 0.05 to 2.12); ratio <1 vs 
controls 1.34 (95% CI 0.28 to 4.14)), but there was no differ-
ence between the two disease groups.
No significant correlations were seen between plasma tau 
concentrations and measures of disease severity (disease dura-
tion, r=0.19; cross-sectional brain volumes, r=0.05 to 0.19) or 
disease progression (serum neurofilament light chain, r=0.01; 
brain atrophy rate, r=−0.01 to 0.22).
No significant correlation was seen between plasma tau and 
either CSF t-tau (r=0.05) or p-tau181 (r=0.05).
dIsCussIoN
Using an ultrasensitive detection method, we have demon-
strated that concentrations of tau in the plasma are significantly 
increased in FTD. Clinically, both bvFTD and PPA (including 
each of the PPA subtypes) have higher concentrations than 
controls, but genetically, increased levels are only seen in the 
MAPT mutation group.
The only group in the study who definitively have tau 
pathology at postmortem are those with MAPT mutations so it is 
of particular interest that this group has raised levels compared 
with controls. Similarly, there were higher concentrations 
in those with nfvPPA who often have tau pathology (particu-
larly those who develop an associated atypical parkinsonian 
syndrome as a few of the cohort here did). In contrast, patients 
with GRN and C9orf72 mutations have TDP-43 pathology and 
do not have increased concentrations. However, svPPA is a 
TDP-43 proteinopathy in the majority of cases and this group 
also has significantly higher levels than controls. At present, the 
included groups do not have postmortem confirmation of the 
underlying pathology to further explore the ability of plasma tau 
to distinguish tau and TDP-43 proteinopathies, but such studies 
are needed to investigate this issue further.
Different MAPT mutations can have differential pathogenic 
effects on tau (eg, splice variants vs those that affect the structure and 
function of the protein). The current cohort of 12 cases contained 
eight with an intronic 10+16 mutation (the most common UK 
mutation), two with R406W and one each with P301S and Q351R 
mutations. Although too small numbers for a formal analysis, 
there were no clear differences between the 10+16 group (where 
levels varied from 0.70 to 5.66) and the other mutations. Further 
studies in larger cohorts of MAPT mutations will be required to 
understand whether there are any true differences in tau concen-
trations between different mutations.
Logopenic variant PPA is usually an atypical variant of Alzhei-
mer’s disease. Raised plasma tau concentrations were seen in this 
group (and also in the subgroup for which the tau/Aβ1-42 ratio 
was >1) compared with controls, consistent with previous studies 
showing increases in typical Alzheimer’s disease.2 However, as 
with other studies, despite the significant group difference, there 
was extensive overlap between the patients and controls. In fact, 
this was the same for all analyses, with a large overlap in values 
between the disease groups and controls, likely precluding the 
use of plasma tau as a useful diagnostic biomarker.
This study did not investigate longitudinal changes in plasma 
tau, and it would be useful to explore this further to see how 
plasma tau changes with disease progression, including analysis 
in the very early stages of disease, as can be studied in presymp-
tomatic genetic FTD cohorts such as the Genetic Frontotemporal 
dementia Initiative (GENFI).7 However, interestingly, in this 
cross-sectional study, plasma tau shows no significant correla-
tion with either measures of disease severity or intensity, and 
therefore, at least in this heterogeneous cohort, does not seem to 
track with disease progression. It will be useful to investigate this 
further in more homogeneous and larger cohorts, for example, 
in those specifically with tau pathology. 7 The patient numbers in 
this study were too small to perform such subanalyses.
In summary, plasma tau concentration is increased in clinical 
subtypes of FTD but only those with MAPT mutations geneti-
cally. Further studies will be needed to investigate the longitu-
dinal change in tau and whether, when applied to larger samples 
with pathological confirmation of tau burden, raised levels 
improve differentiation between patients with FTD with tau and 
TDP-43 pathology. However, while further studies may improve 
understanding of the pathophysiological relevance of plasma tau 
levels, the extensive overlap of levels with healthy controls is 
likely to limit its diagnostic utility.
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